Inpatient management of patients with increasingly virulent community acquired and nosocomial infections, ranging from bacteremia to C. difficile colitis, presents hospitalists with challenging choices.
The US Food and Drug Administration (FDA) today expanded approval of Simponi (golimumab) to treat moderate to severe ulcerative colitis, a chronic inflammatory bowel disease (IBD) that affects some 620,000 Americans.
Researchers using fMRI to study neural activity in IBS patients report that the processing and perception of visceral stimuli can be modulated by psychological and cognitive treatment.
Patients who have IBD, even those who are in clinical remission, often exhibit symptoms consistent with IBS, which can complicate the assessment and management of IBD and lead to unnecessary interventions.
Researchers claim that restricting dietary intake of fermentable short-chain carbohydrates improves GI symptoms in patients with IBS.
